Diabetes Metab J.  2013 Apr;37(2):149-151. 10.4093/dmj.2013.37.2.149.

Is the Indicator Magnifying Window for Insulin Pens Helpful for Elderly Diabetic Patients?

• Lee JH
• Hong ES
• Ohn JH
• Cho YM

• KMID: 2280717
• DOI: http://doi.org/10.4093/dmj.2013.37.2.149

Abstract

Patients with type 2 diabetes who require insulin therapy are commonly elderly and have poor visual acuity. In this study, we examined the clinical usefulness of the indicator magnifying window (IMW) for elderly patients with type 2 diabetes. We recruited 50 patients with type 2 diabetes over the age of 60 who had used insulin pens for glucose control. They were asked to set the insulin pen at randomly selected doses with or without an IMW. We assessed dosing accuracy, convenience, self-confidence, need for eyeglasses, preference, and willingness to recommend the IMW to other patients. Although the IMW did not improve the dosing accuracy or convenience, it significantly decreased the need for eyeglasses. Overall, the clinical usefulness of the IMW is quite limited in elderly patients with type 2 diabetes.

Keyword

Diabetes mellitus; Insulin; Insulin pen

MeSH Terms

Aged
Diabetes Mellitus
Eyeglasses
Glucose
Humans
Insulin
Visual Acuity
Glucose
Insulin

Figure

• 

  Fig. 1 An insulin pen with the indicator magnifying window attached.

Reference

1. Zhang X, Gregg EW, Cheng YJ, Thompson TJ, Geiss LS, Duenas MR, Saaddine JB. Diabetes mellitus and visual impairment: national health and nutrition examination survey, 1999-2004. Arch Ophthalmol. 2008. 126:1421–1427.

2. de Fine Olivarius N, Siersma V, Almind GJ, Nielsen NV. Prevalence and progression of visual impairment in patients newly diagnosed with clinical type 2 diabetes: a 6-year follow up study. BMC Public Health. 2011. 11:80.

3. Ministry for Health, Welfare and Family Affairs: The Third Korea National Health and Nutrition Examination Survey (KNHANES III). Available from: http://knhanes.cdc.go.kr (updated 2006 Jul 8).

4. Lim S, Kim DJ, Jeong IK, Son HS, Chung CH, Koh G, Lee DH, Won KC, Park JH, Park TS, Ahn J, Kim J, Park KG, Ko SH, Ahn YB, Lee I. A nationwide survey about the current status of glycemic control and complications in diabetic patients in 2006: the Committee of the Korean Diabetes Association on the epidemiology of diabetes mellitus. Korean Diabetes J. 2009. 33:48–57.

5. Porte D Jr, Kahn SE. Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes. 2001. 50:Suppl 1. S160–S163.

6. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005. 365:1333–1346.

7. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. American Diabetes Association (ADA). European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012. 35:1364–1379.

8. Hahn CS. The Korean near vision chart. J Korean Ophthalmol Soc. 1964. 5:7–10.

9. Bartos BJ, Cleary ME, Kleinbeck C, Petzinger RA, Sokol-McKay DA, Whittington A, Williams AS. Diabetes and disabilities: assistive tools, services, and information. Diabetes Educ. 2008. 34:597–605.

10. Petzinger RA. Diabetes aids and products for people with visual or physical impairment. Diabetes Educ. 1992. 18:121–138.

11. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998. 20:486–496.

12. Gnanalingham MG, Newland P, Smith CP. Accuracy and reproducibility of low dose insulin administration using pen-injectors and syringes. Arch Dis Child. 1998. 79:59–62.

13. Korytkowski M, Bell D, Jacobsen C, Suwannasari R. FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003. 25:2836–2848.

14. Ignaut DA, Schwartz SL, Sarwat S, Murphy HL. Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen. Diabetes Educ. 2009. 35:789–798.

15. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care. 2004. 27:2495–2497.

16. Williams AS, Schnarrenberger PA. A comparison of dosing accuracy: visually impaired and sighted people using insulin pens. J Diabetes Sci Technol. 2010. 4:514–521.